Hiroshima-based Phoenix Bio Establishes NYC Office

Hiroshima-based bioventure Phoenix Bio provides proprietary PXB-mice, chimeric mice with humanized livers, for new drug research and development. In recent years, the company has seen increasing orders for the mice from drug makers in the U.S. and Europe. Phoenix Bio estimates sales will triple from 2008 to ¥2 billion by 2010. Aiming to establish a manufacturing and testing presence in the U.S., the company is opening a New York City office, which will be staffed with four to five employees and start operation in July. (Click here for more - Japanese language

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.